KBI Biopharma, Inc.

North Carolina

Classification

Private

About

About

Company Overview: KBI Biopharma is a biopharmaceutical company, serving as a leading contract service provider that specializes in supporting the development and manufacturing of biologic drugs. With a commitment to delivering excellence and innovation, KBI Biopharma partners with pharmaceutical and biotechnology companies to provide comprehensive solutions that span the entire drug development lifecycle. The company's expertise, state-of-the-art facilities, and collaborative approach position it as a trusted partner for clients seeking to accelerate their biopharmaceutical programs. Product/Service Line Breakdown: KBI Biopharma offers a diverse range of services and solutions tailored to meet the unique needs of its clients throughout the drug development journey: Bioprocess Development: KBI Biopharma's bioprocess development services involve the optimization and scale-up of biologic manufacturing processes. This includes cell line development, media optimization, and fermentation process optimization. The goal is to enhance productivity, yield, and efficiency while ensuring the consistent production of high-quality biologics. Analytical Services: The company's analytical services encompass a comprehensive suite of testing and characterization methodologies to assess the quality, purity, potency, and stability of biopharmaceutical products. These services are crucial for regulatory compliance, process monitoring, and ensuring product safety. Formulation Development: KBI Biopharma offers formulation development services to design optimized formulations that enhance the stability and performance of biologic drug products. This includes developing appropriate buffer systems, stabilizers, and excipients to maintain the product's integrity over its shelf life. Drug Substance Manufacturing: KBI Biopharma's cGMP-compliant facilities are equipped to handle the manufacturing of biologic drug substances at various scales. The company provides process validation, production optimization, and stringent quality control to ensure the consistent production of high-quality drug substances. Drug Product Manufacturing: KBI Biopharma's capabilities extend to drug product manufacturing, including fill and finish services. This involves the sterile filling of drug substances into vials, syringes, or other delivery systems, followed by packaging and labeling in compliance with regulatory standards. Regulatory Support: The company offers regulatory support services to assist clients in navigating the complex regulatory landscape. This includes compiling necessary documentation for regulatory submissions, participating in audits, and ensuring compliance with applicable guidelines. Integrated Services: KBI Biopharma's integrated services provide clients with end-to-end solutions that streamline the drug development process. This approach facilitates seamless collaboration between different stages of development, optimizing timelines and reducing potential risks.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private